Gaia Griguolo· @GaiaGriguolo · X·· 22 小时前评分70
正文 · 原文
KEYNOTE-B49 presented by @hoperugo at #ESMO26
Addition of pembro to CT in PDL1+ HR+HER2- mBC with no previous CT for metastatic BC
✅️primary PFS endpoint reached (curves opening at tails)
✅️higher magnitude of PFS benefit in CPS >=10
❌️no sign OS difference
@OncoAlert
40 浏览 · 4 赞 · 3 转发 · 0 回复
会议摘要
LBA51按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)
https://esmocongress.esmo.org来源：Gaia Griguolo · x.com